Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Apogee Therapeutics, Inc. (APGE)
USD133.82
+0.17 (+0.13%)
US NASDAQ Healthcare Biotechnology
Address
221 Crescent Street 2453
Waltham, MA, US
Waltham, MA, US
CEO
Michael Thomas Henderson
Website
apogeetherapeutics.com
IPO
2023-07-14
CIK 1974640 ISIN US03770N1019
Description
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
News Sentiment (7d)
Based on only 2 articles — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD133.82
+0.17 (+0.13%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.62
Float Shares
53.08M
Free Float %
85.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.89% | +0.26% | -1.94% | +22.06% | +34.07% | +12.08% | +113.74% | +298.49% | +298.49% | +298.49% | +298.49% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (10 ratings, all time)
Buy
Price Targets & DCF
Current price
133.82
Low
83.00
-38.0%
Consensus
109.44
-18.2%
Median
103.00
-23.0%
High
140.00
+4.6%
DCF (Unlevered)
2.00
-98.5%
DCF (Levered)
2.02
-98.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
83% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 15 | +1 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
140.00
+4.6%
|
| Last Quarter | 2 |
111.50
-16.7%
|
| Last Year | 11 |
104.91
-21.6%
|
| All Time | 12 |
104.08
-22.2%
|
Quality scores
Altman Z-Score
80.90
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-27.9% Q1'26: -11.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-156.5% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+10.0% Q1'26: +19.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.03× Q1'26: -0.02× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 11 EPS Ana. |
Dec 2027 13 Rev. Ana. 11 EPS Ana. |
Dec 2028 11 Rev. Ana. 11 EPS Ana. |
Dec 2029 5 Rev. Ana. 4 EPS Ana. |
Dec 2030 5 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
—
— – —
|
4.17M
4.01M – 4.33M
|
6.25M
6.25M – 6.25M
+50.0% YoY
|
185.41M
185.41M – 185.41M
+2,866.6% YoY
|
817.53M
817.53M – 817.53M
+340.9% YoY
|
| EBITDA |
-216.68M
|
-284.18M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-216.87M
|
-285.60M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-182.15M
est: -179.31M (-1.6%)
|
-255.84M
est: -255.84M (+0.0%)
|
-320.00M
-343.96M – -229.71M
-25.1% YoY
|
-406.83M
-418.45M – -280.56M
-27.1% YoY
|
-527.67M
-743.93M – -299.00M
-29.7% YoY
|
-379.69M
-379.69M – -379.69M
+28.0% YoY
|
-68.88M
-68.88M – -68.88M
+81.9% YoY
|
| SGA |
49.01M
|
70.88M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-3.30
est: -3.24 (-1.9%)
|
-4.22
est: -4.20 (-0.6%)
|
-4.58
-5.67 – -3.78
-9.1% YoY
|
-5.41
-6.89 – -4.62
-18.2% YoY
|
-6.61
-12.26 – -4.93
-22.2% YoY
|
-6.26
-6.26 – -6.26
+5.3% YoY
|
-1.13
-1.13 – -1.13
+81.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
72
Total invested
578.85M
Insider transactions (90d)
4
Beneficial owners (>5%)
31
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Abigail P. Johnson | 7.50M | 16.67% | — | — | 7.50M | — | IN | Delaware | 2024-11-12 | ↗ |
| 2 | FMR LLC | 7.50M | 16.67% | 7.50M | — | 7.50M | — | HC | Delaware | 2024-11-12 | ↗ |
| 3 | Wellington Group Holdings LLP | 4.81M | 10.70% | — | 4.51M | — | — | HC | Massachusetts | 2024-10-04 | ↗ |
| 4 | Wellington Investment Advisors Holdings LLP | 4.81M | 10.70% | — | 4.51M | — | — | HC | Massachusetts | 2024-10-04 | ↗ |
| 5 | Wellington Management Group LLP | 4.81M | 10.70% | — | 4.51M | — | — | HC | Massachusetts | 2024-10-04 | ↗ |
| 6 | Wellington Management Company LLP | 4.70M | 10.44% | — | 4.51M | — | — | IA | Massachusetts | 2024-10-04 | ↗ |
| 7 | Fairmount Healthcare Fund II LP | 3.91M | 9.99% | — | 3.91M | — | 11.00 | PN | — | 2023-07-21 | ↗ |
| 8 | Koh, Bong | 3.89M | 9.99% | — | 3.89M | — | 10.00 | IN | United States | 2023-07-28 | ↗ |
| 9 | Shah, Nimish | 3.89M | 9.99% | — | 3.89M | — | 10.00 | IN | United States | 2023-07-28 | ↗ |
| 10 | VHCP Co-Investment Holdings III, LLC | 3.89M | 9.99% | — | 3.89M | — | 10.00 | OO | Delaware | 2023-07-28 | ↗ |
| 11 | VHCP Management EG, LLC | 3.89M | 9.99% | — | 3.89M | — | 10.00 | OO | Delaware | 2023-07-28 | ↗ |
| 12 | VHCP Management III, LLC | 3.89M | 9.99% | — | 3.89M | — | 10.00 | OO | Delaware | 2023-07-28 | ↗ |
| 13 | Venrock Healthcare Capital Partners EG, L.P. | 3.89M | 9.99% | — | 3.89M | — | 10.00 | PN | Delaware | 2023-07-28 | ↗ |
| 14 | Venrock Healthcare Capital Partners III, L.P. | 3.89M | 9.99% | — | 3.89M | — | 10.00 | PN | Delaware | 2023-07-28 | ↗ |
| 15 | Fairmount Funds Management LLC | 3.80M | 9.99% | — | 3.80M | — | 11.00 | IA | — | 2023-07-21 | ↗ |
| 16 | Peter Harwin | 3.80M | 9.99% | — | 3.80M | — | 11.00 | IN | — | 2023-07-21 | ↗ |
| 17 | Tomas Kiselak | 3.80M | 9.99% | — | 3.80M | — | 11.00 | IN | — | 2023-07-21 | ↗ |
| 18 | David Kroin | 3.02M | 8.87% | — | 3.02M | — | — | HC, IN | Delaware | 2023-07-24 | ↗ |
| 19 | Deep Track Biotechnology Master Fund, Ltd. | 3.02M | 8.87% | — | 3.02M | — | — | CO | Delaware | 2023-07-24 | ↗ |
| 20 | Deep Track Capital, LP | 3.02M | 8.87% | — | 3.02M | — | — | IA, OO | Delaware | 2023-07-24 | ↗ |
| 21 | (1) BlackRock, Inc. | 2.98M | 6.60% | 2.94M | — | 2.98M | — | HC | Delaware | 2024-11-08 | ↗ |
| 22 | DRIEHAUS CAPITAL MANAGEMENT LLC | 2.53M | 5.63% | — | 2.53M | — | 2.53M | IA | — | 2024-11-14 | ↗ |
| 23 | Peter Kolchinsky | 1.98M | 5.30% | — | 1.98M | — | — | HC, IN | Delaware | 2024-02-14 | ↗ |
| 24 | RA Capital Management, L.P. | 1.98M | 5.30% | — | 1.98M | — | — | IA, PN | Delaware | 2024-02-14 | ↗ |
| 25 | Rajeev Shah | 1.98M | 5.30% | — | 1.98M | — | — | HC, IN | Delaware | 2024-02-14 | ↗ |
| 26 | AI Biotechnology LLC | 1.94M | 5.22% | — | 1.94M | — | 1.94M | OO | United States of America | 2023-11-03 | ↗ |
| 27 | Access Industries Holdings LLC | 1.94M | 5.22% | — | 1.94M | — | 1.94M | OO | United States of America | 2023-11-03 | ↗ |
| 28 | Access Industries Management, LLC | 1.94M | 5.22% | — | 1.94M | — | 1.94M | OO | United States of America | 2023-11-03 | ↗ |
| 29 | Len Blavatnik | 1.94M | 5.22% | — | 1.94M | — | 1.94M | IN | United States of America | 2023-11-03 | ↗ |
| 30 | Fairmount Healthcare Co-Invest II LP | 892.5K | 2.40% | — | 892.5K | — | 11.00 | PN | — | 2023-07-21 | ↗ |
| 31 | Fairmount Healthcare Fund LP | 277.3K | 0.74% | — | 277.3K | — | 11.00 | PN | — | 2023-07-21 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
72
-143 vs prev Q
New positions
20
Closed positions
156
Increased
52
Reduced
14
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 192.0K +192.0K (+100.0%) | 14.49B +14.5B (+100.0%) | 0.33% +0.327 pp | 3.58% +3.581 pp | USD75.48 +0.0% | 1 qtrs NEW |
| 2 | VR ADVISER, LLC | 8.49M +— (+0.0%) | 641.08M +303.6M (+90.0%) | 14.45% -0.085 pp | 31.67% +12.673 pp | USD21.30 +254.4% | 10 qtrs — |
| 3 | FMR LLC | 8.23M +1.3M (+18.9%) | 620.83M +346.0M (+125.9%) | 13.99% +2.157 pp | 0.03% +0.017 pp | USD40.29 +87.3% | 10 qtrs — |
| 4 | WELLINGTON MANAGEMENT GROUP LLP | 4.75M +22.9K (+0.5%) | 358.27M +170.6M (+90.9%) | 8.08% -0.009 pp | 0.06% +0.030 pp | USD41.01 +84.1% | 10 qtrs — |
| 5 | BLACKROCK, INC. | 3.78M +1.1M (+40.9%) | 285.62M +178.9M (+167.6%) | 6.44% +1.841 pp | 0.00% +0.003 pp | USD62.77 +20.2% | 6 qtrs — |
| 6 | VANGUARD GROUP INC | 2.86M +612.2K (+27.3%) | 215.71M +126.5M (+141.8%) | 4.86% +1.019 pp | 0.00% +0.002 pp | USD47.28 +59.6% | 10 qtrs — |
| 7 | T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 2.73M +2.7M (+189,522.2%) | 206.25M +206.2M (+355,496.6%) | 4.65% +4.647 pp | 0.13% +0.130 pp | USD75.46 +0.0% | 3 qtrs — |
| 8 | RTW INVESTMENTS, LP | 2.71M +— (+0.0%) | 204.71M +97.0M (+90.0%) | 4.61% -0.027 pp | 2.05% +0.723 pp | USD28.10 +168.6% | 10 qtrs — |
| 9 | PERCEPTIVE ADVISORS LLC | 2.33M +978.7K (+72.4%) | 175.92M +122.2M (+227.5%) | 3.97% +1.652 pp | 3.14% +1.585 pp | USD48.82 +54.6% | 10 qtrs — |
| 10 | DRIEHAUS CAPITAL MANAGEMENT LLC | 2.18M +25.2K (+1.2%) | 164.83M +79.1M (+92.2%) | 3.72% +0.021 pp | 1.12% +0.505 pp | USD41.03 +84.0% | 10 qtrs — |
| 11 | JANUS HENDERSON GROUP PLC | 2.06M +1.6M (+324.4%) | 155.70M +136.4M (+706.4%) | 3.51% +2.678 pp | 0.07% +0.061 pp | USD68.47 +10.2% | 10 qtrs — |
| 12 | FAIRMOUNT FUNDS MANAGEMENT LLC | 2.05M +— (+0.0%) | 154.63M +73.2M (+90.0%) | 3.49% -0.021 pp | 11.77% +4.447 pp | USD21.30 +254.4% | 10 qtrs — |
| 13 | STATE STREET CORP | 1.69M +34.6K (+2.1%) | 127.58M +61.8M (+94.0%) | 2.88% +0.042 pp | 0.00% +0.002 pp | USD49.09 +53.8% | 10 qtrs — |
| 14 | JPMORGAN CHASE & CO | 1.37M +235.3K (+20.7%) | 103.64M +58.4M (+129.3%) | 2.34% +0.389 pp | 0.01% +0.004 pp | USD44.51 +69.6% | 10 qtrs — |
| 15 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.24M +486.6K (+64.8%) | 93.38M +63.6M (+213.1%) | 2.10% +0.820 pp | 0.01% +0.007 pp | USD53.60 +40.8% | 10 qtrs — |
| 16 | AFFINITY ASSET ADVISORS, LLC | 1.23M +61.5K (+5.2%) | 93.21M +46.6M (+99.9%) | 2.10% +0.093 pp | 5.31% +1.250 pp | USD38.59 +95.6% | 10 qtrs — |
| 17 | PARADIGM BIOCAPITAL ADVISORS LP | 1.12M -398.5K (-26.2%) | 84.78M +24.3M (+40.2%) | 1.91% -0.693 pp | 2.16% +0.445 pp | USD48.89 +54.4% | 8 qtrs — |
| 18 | ALLIANCEBERNSTEIN L.P. | 1.09M -325.5K (-22.9%) | 82.55M +26.2M (+46.4%) | 1.86% -0.568 pp | 0.03% +0.008 pp | USD53.40 +41.3% | 9 qtrs — |
| 19 | GEODE CAPITAL MANAGEMENT, LLC | 1.06M +166.9K (+18.7%) | 79.96M +44.5M (+125.5%) | 1.80% +0.275 pp | 0.00% +0.003 pp | USD46.89 +61.0% | 10 qtrs — |
| 20 | UBS GROUP AG | 974.8K +175.4K (+21.9%) | 73.58M +41.8M (+131.7%) | 1.66% +0.290 pp | 0.01% +0.007 pp | USD46.73 +61.5% | 10 qtrs — |
| 21 | MERCER GLOBAL ADVISORS INC /ADV | 890.7K -79.9K (-8.2%) | 67.23M +28.7M (+74.3%) | 1.52% -0.146 pp | 0.10% +0.038 pp | USD40.67 +85.6% | 5 qtrs — |
| 22 | MORGAN STANLEY | 890.3K +425.3K (+91.5%) | 67.20M +48.7M (+263.8%) | 1.51% +0.719 pp | 0.00% +0.003 pp | USD56.67 +33.2% | 10 qtrs — |
| 23 | BANK OF AMERICA CORP /DE/ | 793.7K +399.8K (+101.5%) | 59.91M +44.3M (+282.8%) | 1.35% +0.676 pp | 0.00% +0.003 pp | USD56.05 +34.7% | 10 qtrs — |
| 24 | CITADEL ADVISORS LLC | 767.0K -402.3K (-34.4%) | 57.89M +11.4M (+24.6%) | 1.31% -0.696 pp | 0.01% +0.002 pp | USD41.40 +82.3% | 7 qtrs — |
| 25 | JENNISON ASSOCIATES LLC | 578.6K +578.6K (+100.0%) | 43.67M +43.7M (+100.0%) | 0.98% +0.985 pp | 0.03% +0.026 pp | USD75.48 +0.0% | 9 qtrs — |
| 26 | BRAIDWELL LP | 575.1K -863.7K (-60.0%) | 43.41M -13.8M (-24.1%) | 0.98% -1.484 pp | 1.39% -0.308 pp | USD47.04 +60.5% | 10 qtrs — |
| 27 | NOVO HOLDINGS A/S | 570.0K +70.0K (+14.0%) | 43.02M +23.2M (+116.6%) | 0.97% +0.114 pp | 3.34% +2.061 pp | USD47.04 +60.5% | 3 qtrs — |
| 28 | GOLDMAN SACHS GROUP INC | 565.4K -34.2K (-5.7%) | 42.68M +18.9M (+79.1%) | 0.96% -0.064 pp | 0.01% +0.002 pp | USD44.07 +71.3% | 10 qtrs — |
| 29 | VESTAL POINT CAPITAL, LP | 550.0K +125.0K (+29.4%) | 41.51M +24.6M (+145.9%) | 0.94% +0.208 pp | 1.41% +0.649 pp | USD47.86 +57.7% | 2 qtrs — |
| 30 | SOFINNOVA INVESTMENTS, INC. | 534.8K -30.6K (-5.4%) | 40.37M +17.9M (+79.7%) | 0.91% -0.058 pp | 1.74% +0.512 pp | USD40.23 +87.6% | 3 qtrs — |
| 31 | POLAR CAPITAL HOLDINGS PLC | 503.5K -20.6K (-3.9%) | 38.01M +17.2M (+82.5%) | 0.86% -0.040 pp | 0.15% +0.047 pp | USD37.49 +101.3% | 4 qtrs — |
| 32 | AVORO CAPITAL ADVISORS LLC | 500.0K +500.0K (+100.0%) | 37.74M +37.7M (+100.0%) | 0.85% +0.851 pp | 0.36% +0.363 pp | USD75.48 +0.0% | 1 qtrs NEW |
| 33 | FRONTIER CAPITAL MANAGEMENT CO LLC | 480.5K +106.0K (+28.3%) | 36.26M +21.4M (+143.8%) | 0.82% +0.177 pp | 0.38% +0.252 pp | USD53.47 +41.2% | 8 qtrs — |
| 34 | FIRST TURN MANAGEMENT, LLC | 474.8K +72.0K (+17.9%) | 35.84M +19.8M (+124.0%) | 0.81% +0.119 pp | 4.10% +1.692 pp | USD48.48 +55.7% | 8 qtrs — |
| 35 | FRANKLIN RESOURCES INC | 451.0K -279.8K (-38.3%) | 34.04M +5.0M (+17.3%) | 0.77% -0.483 pp | 0.01% +0.001 pp | USD22.18 +240.3% | 10 qtrs — |
| 36 | EVENTIDE ASSET MANAGEMENT, LLC | 436.0K +436.0K (+100.0%) | 32.91M +32.9M (+100.0%) | 0.74% +0.742 pp | 0.51% +0.514 pp | USD75.48 +0.0% | 1 qtrs NEW |
| 37 | OPALEYE MANAGEMENT INC. | 388.3K +25.0K (+6.9%) | 29.31M +14.9M (+103.1%) | 0.66% +0.039 pp | 3.87% +1.826 pp | USD42.03 +79.6% | 2 qtrs — |
| 38 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 381.4K +61.5K (+19.2%) | 28.79M +16.1M (+126.5%) | 0.65% +0.101 pp | 0.00% +0.002 pp | USD45.76 +64.9% | 10 qtrs — |
| 39 | GREAT POINT PARTNERS LLC | 374.0K +70.0K (+23.0%) | 28.23M +16.2M (+133.7%) | 0.64% +0.116 pp | 9.15% +4.172 pp | USD46.42 +62.6% | 2 qtrs — |
| 40 | NORTHERN TRUST CORP | 327.4K +42.9K (+15.1%) | 24.71M +13.4M (+118.6%) | 0.56% +0.070 pp | 0.00% +0.002 pp | USD46.05 +63.9% | 10 qtrs — |
| 41 | PICTET ASSET MANAGEMENT HOLDING SA | 312.9K +312.9K (+100.0%) | 23.62M +23.6M (+100.0%) | 0.53% +0.532 pp | 0.02% +0.023 pp | USD75.48 +0.0% | 1 qtrs NEW |
| 42 | FIRST LIGHT ASSET MANAGEMENT, LLC | 285.0K +285.0K (+100.0%) | 21.51M +21.5M (+100.0%) | 0.48% +0.485 pp | 1.64% +1.645 pp | USD75.48 +0.0% | 1 qtrs NEW |
| 43 | LOOMIS SAYLES & CO L P | 255.4K +255.4K (+100.0%) | 19.28M +19.3M (+100.0%) | 0.43% +0.435 pp | 0.02% +0.023 pp | USD75.48 +0.0% | 1 qtrs NEW |
| 44 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 240.0K +5.0K (+2.1%) | 18.12M +8.8M (+94.0%) | 0.41% +0.006 pp | 0.03% +0.013 pp | USD42.20 +78.9% | 10 qtrs — |
| 45 | DIADEMA PARTNERS LP | 211.1K +83.7K (+65.7%) | 15.93M +10.9M (+214.8%) | 0.36% +0.141 pp | 2.74% +1.450 pp | USD53.18 +41.9% | 4 qtrs — |
| 46 | WOODLINE PARTNERS LP | 210.5K +153.1K (+267.2%) | 15.89M +13.6M (+597.6%) | 0.36% +0.260 pp | 0.06% +0.051 pp | USD67.81 +11.3% | 10 qtrs — |
| 47 | CANDRIAM S.C.A. | 191.3K +65.2K (+51.7%) | 14.44M +9.4M (+188.3%) | 0.33% +0.110 pp | 0.07% +0.046 pp | USD51.92 +45.4% | 2 qtrs — |
| 48 | MILLENNIUM MANAGEMENT LLC | 140.7K -289.7K (-67.3%) | 10.62M -6.5M (-37.9%) | 0.24% -0.497 pp | 0.00% -0.003 pp | USD42.76 +76.5% | 9 qtrs — |
| 49 | BARCLAYS PLC | 133.2K -231.9K (-63.5%) | 10.05M -11.4M (-53.1%) | 0.23% -0.398 pp | 0.00% -0.003 pp | USD49.68 +51.9% | 9 qtrs — |
| 50 | PARKMAN HEALTHCARE PARTNERS LLC | 130.1K +24.2K (+22.9%) | 9.82M +5.6M (+133.5%) | 0.22% +0.040 pp | 0.93% +0.496 pp | USD48.64 +55.2% | 5 qtrs — |
| 51 | TD ASSET MANAGEMENT INC | 129.3K +46.1K (+55.3%) | 9.76M +6.5M (+195.1%) | 0.22% +0.078 pp | 0.01% +0.005 pp | USD52.75 +43.1% | 10 qtrs — |
| 52 | FEDERATED HERMES, INC. | 127.9K +127.9K (+100.0%) | 9.66M +9.7M (+100.0%) | 0.22% +0.218 pp | 0.02% +0.016 pp | USD75.48 +0.0% | 1 qtrs NEW |
| 53 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 127.6K -3.8K (-2.9%) | 9.63M +4.4M (+84.5%) | 0.22% -0.008 pp | 0.02% +0.007 pp | USD45.06 +67.5% | 5 qtrs — |
| 54 | CAPITAL WORLD INVESTORS | 127.6K +— (+0.0%) | 9.63M +4.6M (+90.0%) | 0.22% -0.001 pp | 0.00% +0.001 pp | USD45.30 +66.6% | 5 qtrs — |
| 55 | KENNEDY CAPITAL MANAGEMENT LLC | 125.0K +928.0 (+0.7%) | 9.43M +4.5M (+91.4%) | 0.21% +0.000 pp | 0.20% +0.091 pp | USD42.88 +76.0% | 8 qtrs — |
| 56 | AMERIPRISE FINANCIAL INC | 122.9K +19.7K (+19.1%) | 9.28M +5.2M (+126.4%) | 0.21% +0.033 pp | 0.00% +0.001 pp | USD45.68 +65.2% | 5 qtrs — |
| 57 | NUVEEN, LLC | 121.1K +37.8K (+45.3%) | 9.14M +5.8M (+176.1%) | 0.21% +0.063 pp | 0.00% +0.002 pp | USD49.25 +53.3% | 4 qtrs — |
| 58 | BANK OF NEW YORK MELLON CORP | 118.1K +10.5K (+9.8%) | 8.91M +4.6M (+108.6%) | 0.20% +0.017 pp | 0.00% +0.001 pp | USD44.08 +71.2% | 10 qtrs — |
| 59 | NICHOLAS INVESTMENT PARTNERS, LP | 112.9K +112.9K (+100.0%) | 8.52M +8.5M (+100.0%) | 0.19% +0.192 pp | 0.62% +0.621 pp | USD75.48 +0.0% | 1 qtrs NEW |
| 60 | ARROWMARK COLORADO HOLDINGS LLC | 109.4K +— (+0.0%) | 8.26M +3.9M (+90.0%) | 0.19% -0.001 pp | 0.18% +0.101 pp | USD33.30 +126.7% | 10 qtrs — |
| 61 | VICTORY CAPITAL MANAGEMENT INC | 108.3K -108.9K (-50.2%) | 8.17M -457.9K (-5.3%) | 0.18% -0.188 pp | 0.00% 0.000 pp | USD53.55 +41.0% | 10 qtrs — |
| 62 | SCHRODER INVESTMENT MANAGEMENT GROUP | 105.0K -110.8K (-51.4%) | 7.95M -642.3K (-7.5%) | 0.18% -0.191 pp | 0.01% -0.001 pp | USD39.38 +91.7% | 7 qtrs — |
| 63 | TWO SIGMA INVESTMENTS, LP | 105.2K -17.1K (-14.0%) | 7.94M +3.1M (+63.4%) | 0.18% -0.030 pp | 0.01% +0.004 pp | USD43.61 +73.1% | 9 qtrs — |
| 64 | NEUBERGER BERMAN GROUP LLC | 99.6K +99.6K (+100.0%) | 7.52M +7.5M (+100.0%) | 0.17% +0.170 pp | 0.01% +0.006 pp | USD75.48 +0.0% | 1 qtrs NEW |
| 65 | GRANAHAN INVESTMENT MANAGEMENT, LLC | 94.7K -37.7K (-28.5%) | 7.15M +1.9M (+35.9%) | 0.16% -0.065 pp | 0.31% +0.091 pp | USD53.31 +41.6% | 6 qtrs — |
| 66 | HIGHVISTA STRATEGIES LLC | 89.2K -17.9K (-16.7%) | 6.74M +2.5M (+58.3%) | 0.15% -0.032 pp | 1.73% +0.691 pp | USD50.00 +51.0% | 8 qtrs — |
| 67 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 80.8K +17.6K (+27.8%) | 6.12M +3.6M (+143.6%) | 0.14% +0.029 pp | 0.01% +0.003 pp | USD48.03 +57.2% | 10 qtrs — |
| 68 | STEMPOINT CAPITAL LP | 80.6K +80.6K (+100.0%) | 6.08M +6.1M (+100.0%) | 0.14% +0.137 pp | 1.04% +1.043 pp | USD75.48 +0.0% | 3 qtrs — |
| 69 | DEUTSCHE BANK AG\ | 79.4K +2.8K (+3.7%) | 5.99M +2.9M (+97.0%) | 0.14% +0.004 pp | 0.00% +0.001 pp | USD43.78 +72.4% | 10 qtrs — |
| 70 | HUDSON BAY CAPITAL MANAGEMENT LP | 79.0K +79.0K (+100.0%) | 5.96M +6.0M (+100.0%) | 0.13% +0.134 pp | 0.02% +0.020 pp | USD75.48 +0.0% | 1 qtrs NEW |
| 71 | NOMURA HOLDINGS INC | 76.9K +76.9K (+100.0%) | 5.80M +5.8M (+100.0%) | 0.13% +0.131 pp | 0.01% +0.008 pp | USD75.48 +0.0% | 1 qtrs NEW |
| 72 | SG AMERICAS SECURITIES, LLC | 73.3K -61.0K (-45.4%) | 5.53M +197.0K (+3.7%) | 0.12% -0.105 pp | 0.01% -0.011 pp | USD39.73 +90.0% | 2 qtrs — |
| 73 | INVESCO LTD. | 70.7K +41.5K (+142.6%) | 5.34M +4.2M (+360.9%) | 0.12% +0.070 pp | 0.00% +0.001 pp | USD66.59 +13.4% | 10 qtrs — |
| 74 | BOXER CAPITAL MANAGEMENT, LLC | 70.0K +20.0K (+40.0%) | 5.28M +3.3M (+166.0%) | 0.12% +0.034 pp | 1.16% +0.523 pp | USD49.94 +51.1% | 2 qtrs — |
| 75 | PLATINUM INVESTMENT MANAGEMENT LTD | 69.2K -24.5K (-26.2%) | 5.22M +1.5M (+40.3%) | 0.12% -0.043 pp | 1.21% +0.967 pp | USD22.72 +232.2% | 10 qtrs — |
| 76 | D. E. SHAW & CO., INC. | 63.3K -37.3K (-37.1%) | 4.77M +778.5K (+19.5%) | 0.11% -0.065 pp | 0.00% +0.000 pp | USD43.21 +74.7% | 7 qtrs — |
| 77 | SWISS NATIONAL BANK | 62.9K +19.5K (+44.9%) | 4.75M +3.0M (+175.3%) | 0.11% +0.033 pp | 0.00% +0.002 pp | USD48.92 +54.3% | 9 qtrs — |
| 78 | SIMPLEX TRADING, LLC | 62.8K +62.8K (+100.0%) | 4.74M +4.7M (+100.0%) | 0.11% +0.107 pp | 0.00% +0.003 pp | USD75.48 +0.0% | 1 qtrs NEW |
| 79 | PRUDENTIAL FINANCIAL INC | 54.3K +41.4K (+322.2%) | 4.10M +3.6M (+702.2%) | 0.09% +0.070 pp | 0.00% +0.004 pp | USD68.09 +10.9% | 8 qtrs — |
| 80 | BLACKSTONE INC. | 51.8K -138.5K (-72.8%) | 3.91M -3.7M (-48.3%) | 0.09% -0.238 pp | 0.02% -0.015 pp | USD31.35 +140.8% | 10 qtrs — |
| 81 | MARSHALL WACE, LLP | 50.7K +43.7K (+622.1%) | 3.83M +3.6M (+1,271.9%) | 0.09% +0.074 pp | 0.00% +0.003 pp | USD71.07 +6.2% | 7 qtrs — |
| 82 | SEVEN GRAND MANAGERS, LLC | 50.0K +50.0K (+100.0%) | 3.77M +3.8M (+100.0%) | 0.09% +0.085 pp | 0.29% +0.287 pp | USD75.48 +0.0% | 1 qtrs NEW |
| 83 | RUSSELL INVESTMENTS GROUP, LTD. | 50.0K +6.3K (+14.5%) | 3.77M +2.0M (+117.5%) | 0.09% +0.010 pp | 0.00% +0.002 pp | USD45.84 +64.7% | 7 qtrs — |
| 84 | UBS ASSET MANAGEMENT AMERICAS INC | 49.8K +18.6K (+59.8%) | 3.76M +2.5M (+203.6%) | 0.08% +0.031 pp | 0.00% +0.001 pp | USD53.41 +41.3% | 7 qtrs — |
| 85 | RAFFERTY ASSET MANAGEMENT, LLC | 48.6K -17.2K (-26.1%) | 3.67M +1.1M (+40.4%) | 0.08% -0.030 pp | 0.01% +0.004 pp | USD53.42 +41.3% | 8 qtrs — |
| 86 | RHUMBLINE ADVISERS | 46.0K -1.8K (-3.8%) | 3.47M +1.6M (+82.7%) | 0.08% -0.004 pp | 0.00% +0.001 pp | USD44.05 +71.4% | 10 qtrs — |
| 87 | ALPS ADVISORS INC | 44.9K +22.4K (+99.6%) | 3.39M +2.5M (+279.2%) | 0.08% +0.038 pp | 0.02% +0.015 pp | USD57.19 +32.0% | 7 qtrs — |
| 88 | WELLS FARGO & COMPANY/MN | 42.5K +20.5K (+93.3%) | 3.21M +2.3M (+267.2%) | 0.07% +0.035 pp | 0.00% +0.000 pp | USD63.78 +18.3% | 10 qtrs — |
| 89 | BANQUE PICTET & CIE SA | 41.8K +41.8K (+100.0%) | 3.16M +3.2M (+100.0%) | 0.07% +0.071 pp | 0.02% +0.019 pp | USD75.48 +0.0% | 1 qtrs NEW |
| 90 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 41.7K -37.9K (-47.6%) | 3.15M -15.0K (-0.5%) | 0.07% -0.065 pp | 0.00% +0.000 pp | USD42.27 +78.6% | 7 qtrs — |
| 91 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 39.8K +39.6K (+19,625.7%) | 3.01M +3.0M (+37,487.5%) | 0.07% +0.067 pp | 0.00% +0.003 pp | USD75.32 +0.2% | 3 qtrs — |
| 92 | ABRDN PLC | 36.1K -18.7K (-34.1%) | 2.73M +549.4K (+25.3%) | 0.06% -0.032 pp | 0.00% +0.001 pp | USD39.73 +90.0% | 2 qtrs — |
| 93 | COMERICA BANK | 35.9K +338.0 (+1.0%) | 2.71M +1.3M (+91.8%) | 0.06% +0.000 pp | 0.01% +0.006 pp | USD49.67 +52.0% | 10 qtrs — |
| 94 | CINCTIVE CAPITAL MANAGEMENT LP | 33.3K +33.3K (+100.0%) | 2.51M +2.5M (+100.0%) | 0.06% +0.057 pp | 0.14% +0.136 pp | USD75.48 +0.0% | 1 qtrs NEW |
| 95 | LEGAL & GENERAL GROUP PLC | 32.9K +5.2K (+18.8%) | 2.48M +1.4M (+125.6%) | 0.06% +0.009 pp | 0.00% +0.000 pp | USD49.66 +52.0% | 10 qtrs — |
| 96 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 30.8K +9.4K (+43.8%) | 2.32M +1.5M (+173.2%) | 0.05% +0.016 pp | 0.00% +0.002 pp | USD47.71 +58.2% | 10 qtrs — |
| 97 | TUDOR INVESTMENT CORP ET AL | 30.0K +30.0K (+100.0%) | 2.27M +2.3M (+100.0%) | 0.05% +0.051 pp | 0.00% +0.004 pp | USD75.48 +0.0% | 1 qtrs NEW |
| 98 | SCHONFELD STRATEGIC ADVISORS LLC | 29.1K +29.1K (+100.0%) | 2.20M +2.2M (+100.0%) | 0.05% +0.050 pp | 0.01% +0.010 pp | USD75.48 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.18
Bearish
Ratio by volume
0.23
Bearish
Buys
3
Sells
17
Shares acquired
11.3K
Shares disposed
48.3K
Cash buys
—
Cash sales
14.00
Net activity
-37,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | Dambkowski Carl | Officer | M-Exempt | A | Common Stock | 4,125 | 22.86 | 94.3K | 212,523 | D | ↗ |
| 2026-05-01 | Henderson Jane | Officer | S-Sale | D | Common Stock | 811 | 81.02 | 65.7K | 174,560 | D | ↗ |
| 2026-04-16 | Henderson Jane | Officer | S-Sale | D | Common Stock | 2,000 | 90.00 | 180.0K | 175,371 | D | ↗ |
| 2026-04-16 | HENDERSON MICHAEL THOMAS | Director / Officer | M-Exempt | A | Common Stock | 3,000 | 22.86 | 68.6K | 1,135,987 | D | ↗ |
| 2026-04-08 | HENDERSON MICHAEL THOMAS | Director / Officer | S-Sale | D | Common Stock | 17,800 | 82.48 | 1.47M | 1,135,187 | D | ↗ |
| 2026-04-01 | Henderson Jane | Officer | S-Sale | D | Common Stock | 1,100 | 85.46 | 94.0K | 177,371 | D | ↗ |
| 2026-04-01 | Dambkowski Carl | Officer | S-Sale | D | Common Stock | 100 | 85.89 | 8.6K | 208,398 | D | ↗ |
| 2026-03-25 | Henderson Jane | Officer | S-Sale | D | Common Stock | 2,000 | 85.00 | 170.0K | 179,371 | D | ↗ |
| 2026-03-11 | HENDERSON MICHAEL THOMAS | Director / Officer | S-Sale | D | Common Stock | 8,363 | 74.29 | 621.3K | 1,164,624 | D | ↗ |
| 2026-03-04 | Dambkowski Carl | Officer | S-Sale | D | Common Stock | 2,075 | 71.98 | 149.4K | 209,973 | D | ↗ |
| 2026-03-02 | Henderson Jane | Officer | S-Sale | D | Common Stock | 300 | 68.27 | 20.5K | 183,071 | D | ↗ |
| 2026-02-11 | HENDERSON MICHAEL THOMAS | Director / Officer | S-Sale | D | Common Stock | 11,494 | 62.96 | 723.7K | 1,181,493 | D | ↗ |
| 2026-02-04 | Dambkowski Carl | Officer | S-Sale | D | Common Stock | 1,299 | 66.85 | 86.8K | 211,448 | D | ↗ |
| 2026-02-02 | Henderson Jane | Officer | S-Sale | D | Common Stock | 792 | 65.21 | 51.6K | 184,579 | D | ↗ |
| 2026-01-22 | Fairmount Funds Management LLC | Director | S-Sale | D | Common Stock | 1,750,000 | 76.30 | 133.53M | 298,647 | I | ↗ |
| 2026-01-14 | HENDERSON MICHAEL THOMAS | Director / Officer | S-Sale | D | Common Stock | 2,374 | 81.00 | 192.3K | 1,200,697 | D | ↗ |
| 2026-01-07 | Dambkowski Carl | Officer | M-Exempt | A | Common Stock | 14,025 | 22.86 | 320.6K | 231,223 | D | ↗ |
| 2026-01-06 | Henderson Jane | Officer | S-Sale | D | Common Stock | 2,000 | 80.00 | 160.0K | 185,371 | D | ↗ |
| 2026-01-02 | Henderson Jane | Officer | S-Sale | D | Common Stock | 4,080 | 75.20 | 306.8K | 187,371 | D | ↗ |
| 2026-01-02 | HENDERSON MICHAEL THOMAS | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 253,016 | 75.78 | 19.17M | 253,016 | D | ↗ |
| 2026-01-02 | Dambkowski Carl | Officer | A-Award | A | Stock Option (Right to Buy) | 83,690 | 75.78 | 6.34M | 83,690 | D | ↗ |
| 2025-12-19 | Henderson Jane | Officer | S-Sale | D | Common Stock | 1,500 | 80.00 | 120.0K | 193,371 | D | ↗ |
| 2025-12-10 | HENDERSON MICHAEL THOMAS | Director / Officer | S-Sale | D | Common Stock | 9,435 | 74.88 | 706.5K | 1,223,552 | D | ↗ |
| 2025-12-04 | Henderson Jane | Officer | S-Sale | D | Common Stock | 1,500 | 75.00 | 112.5K | 194,871 | D | ↗ |
| 2025-12-04 | HENDERSON MICHAEL THOMAS | Director / Officer | S-Sale | D | Common Stock | 40,000 | 75.01 | 3.00M | 1,232,987 | D | ↗ |
| 2025-12-04 | Dambkowski Carl | Officer | S-Sale | D | Common Stock | 10,900 | 75.00 | 817.5K | 271,108 | D | ↗ |
| 2025-11-25 | Henderson Jane | Officer | S-Sale | D | Common Stock | 1,500 | 70.00 | 105.0K | 196,371 | D | ↗ |
| 2025-11-14 | Henderson Jane | Officer | S-Sale | D | Common Stock | 2,000 | 65.00 | 130.0K | 197,871 | D | ↗ |
| 2025-11-13 | HENDERSON MICHAEL THOMAS | Director / Officer | S-Sale | D | Common Stock | 3,340 | 61.93 | 206.8K | 1,289,647 | D | ↗ |
| 2025-11-11 | Henderson Jane | Officer | S-Sale | D | Common Stock | 1,000 | 60.00 | 60.0K | 199,871 | D | ↗ |
| 2025-11-05 | Dambkowski Carl | Officer | S-Sale | D | Common Stock | 2,200 | 54.83 | 120.6K | 288,293 | D | ↗ |
| 2025-10-10 | Shah Nimish P | Director | P-Purchase | A | Pre-Funded Warrants (Right to Buy) | 365,853 | 0.00 | — | 365,853 | I | ↗ |
| 2025-10-01 | Dambkowski Carl | Officer | M-Exempt | A | Common Stock | 2,385 | 22.86 | 54.5K | 289,843 | D | ↗ |
| 2025-09-03 | Dambkowski Carl | Officer | S-Sale | D | Common Stock | 2,535 | 37.82 | 95.9K | 233,738 | D | ↗ |
| 2025-08-06 | Dambkowski Carl | Officer | S-Sale | D | Common Stock | 2,725 | 37.78 | 103.0K | 236,273 | D | ↗ |
| 2025-07-02 | Dambkowski Carl | Officer | M-Exempt | A | Common Stock | 7,365 | 22.86 | 168.4K | 249,088 | D | ↗ |
| 2025-06-17 | Shah Nimish P | Director | A-Award | A | Stock Option (Right to Buy) | 14,461 | 41.66 | 602.4K | 14,461 | D | ↗ |
| 2025-06-17 | McKenna Mark C. | Director | A-Award | A | Stock Option (Right to Buy) | 14,461 | 41.66 | 602.4K | 14,461 | D | ↗ |
| 2025-06-17 | JONES WILLIAM A JR | Director | A-Award | A | Stock Option (Right to Buy) | 14,461 | 41.66 | 602.4K | 14,461 | D | ↗ |
| 2025-06-17 | Gottesdiener Andrew | Director | A-Award | A | Stock Option (Right to Buy) | 14,461 | 41.66 | 602.4K | 14,461 | D | ↗ |
| 2025-06-17 | Fox Jennifer A. | Director | A-Award | A | Stock Option (Right to Buy) | 14,461 | 41.66 | 602.4K | 14,461 | D | ↗ |
| 2025-06-17 | Fairmount Funds Management LLC | Director | A-Award | A | Stock Option (Right to Buy) | 14,461 | 41.66 | 602.4K | 14,461 | I | ↗ |
| 2025-06-17 | Bollinger Lisa | Director | A-Award | A | Stock Option (Right to Buy) | 14,461 | 41.66 | 602.4K | 14,461 | D | ↗ |
| 2025-06-04 | Dambkowski Carl | Officer | S-Sale | D | Common Stock | 2,725 | 36.96 | 100.7K | 241,723 | D | ↗ |
| 2025-05-07 | Dambkowski Carl | Officer | S-Sale | D | Common Stock | 2,725 | 35.75 | 97.4K | 244,448 | D | ↗ |
| 2025-04-02 | Dambkowski Carl | Officer | S-Sale | D | Common Stock | 2,471 | 35.56 | 87.9K | 248,562 | D | ↗ |
| 2025-03-05 | HENDERSON MICHAEL THOMAS | Director / Officer | S-Sale | D | Common Stock | 7,326 | 29.98 | 219.6K | 1,295,661 | D | ↗ |
| 2025-03-05 | Dambkowski Carl | Officer | S-Sale | D | Common Stock | 1,590 | 30.48 | 48.5K | 251,033 | D | ↗ |
| 2025-02-05 | HENDERSON MICHAEL THOMAS | Director / Officer | S-Sale | D | Common Stock | 15,000 | 40.58 | 608.7K | 1,302,987 | D | ↗ |
| 2025-02-05 | Dambkowski Carl | Officer | M-Exempt | A | Common Stock | 795 | 22.86 | 18.2K | 256,143 | D | ↗ |
| 2025-01-31 | HENDERSON MICHAEL THOMAS | Director / Officer | M-Exempt | A | Common Stock | 8,500 | 22.86 | 194.3K | 1,317,987 | D | ↗ |
| 2025-01-08 | HENDERSON MICHAEL THOMAS | Director / Officer | S-Sale | D | Common Stock | 12,132 | 48.72 | 591.1K | 1,312,355 | D | ↗ |
| 2025-01-02 | Dambkowski Carl | Officer | S-Sale | D | Common Stock | 2,486 | 47.21 | 117.4K | 255,448 | D | ↗ |
| 2024-12-12 | McKenna Mark C. | Director | P-Purchase | A | Common Stock | 12,500 | 49.85 | 623.1K | 20,000 | D | ↗ |
| 2024-12-11 | Dambkowski Carl | Officer | M-Exempt | A | Common Stock | 1,815 | 22.86 | 41.5K | 262,613 | D | ↗ |
| 2024-12-09 | Henderson Jane | Officer | A-Award | A | Stock Option (Right to Buy) | 124,962 | 49.07 | 6.13M | 124,962 | D | ↗ |
| 2024-12-09 | HENDERSON MICHAEL THOMAS | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 357,036 | 49.07 | 17.52M | 357,036 | D | ↗ |
| 2024-12-09 | Dambkowski Carl | Officer | A-Award | A | Stock Option (Right to Buy) | 124,962 | 49.07 | 6.13M | 124,962 | D | ↗ |
| 2024-12-04 | HENDERSON MICHAEL THOMAS | Director / Officer | S-Sale | D | Common Stock | 13,328 | 46.50 | 619.8K | 1,326,159 | D | ↗ |
| 2024-12-04 | Dambkowski Carl | Officer | S-Sale | D | Common Stock | 6,665 | 46.07 | 307.1K | 260,798 | D | ↗ |
| 2024-11-06 | HENDERSON MICHAEL THOMAS | Director / Officer | S-Sale | D | Common Stock | 14,000 | 59.17 | 828.4K | 1,340,487 | D | ↗ |
| 2024-11-06 | Dambkowski Carl | Officer | S-Sale | D | Common Stock | 5,326 | 58.91 | 313.8K | 268,802 | D | ↗ |
| 2024-10-02 | HENDERSON MICHAEL THOMAS | Director / Officer | S-Sale | D | Common Stock | 30,288 | 56.07 | 1.70M | 1,364,199 | D | ↗ |
| 2024-10-02 | Dambkowski Carl | Officer | S-Sale | D | Common Stock | 5,740 | 56.16 | 322.4K | 275,053 | D | ↗ |
| 2024-09-04 | HENDERSON MICHAEL THOMAS | Director / Officer | S-Sale | D | Common Stock | 25,641 | 47.28 | 1.21M | 1,408,846 | — | ↗ |
| 2024-09-04 | Dambkowski Carl | Officer | S-Sale | D | Common Stock | 5,878 | 47.49 | 279.1K | 281,580 | — | ↗ |
| 2024-08-23 | Henderson Jane | Officer | S-Sale | D | Common Stock | 6,000 | 48.26 | 289.6K | 200,871 | — | ↗ |
| 2024-08-07 | HENDERSON MICHAEL THOMAS | Director / Officer | S-Sale | D | Common Stock | 32,233 | 40.40 | 1.30M | 1,442,254 | — | ↗ |
| 2024-08-07 | Dambkowski Carl | Officer | S-Sale | D | Common Stock | 6,523 | 40.47 | 264.0K | 288,270 | — | ↗ |
| 2024-01-29 | Fairmount Funds Management LLC | Director | J-Other | A | Common Stock | 51,166 | 0.00 | — | 51,166 | — | ↗ |
| 2023-12-18 | HENDERSON MICHAEL THOMAS | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 398,512 | 22.86 | 9.11M | 398,512 | — | ↗ |
| 2023-07-13 | HENDERSON MICHAEL THOMAS | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 1,489,487 | — | ↗ |
| 2023-07-13 | Fairmount Funds Management LLC | Director | P-Purchase | A | Common Stock | 55,913 | 17.00 | 950.5K | 55,913 | — | ↗ |
Executive team
Top executives
Shares Outstanding
61.85M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Michael Henderson, M.D. Chief Executive Officer | 700.0K | — | — | — | 591.5K | — | 1.29M | 0.00% | ↗ |
| 2 | 2025 | Carl Dambkowski, M.D. Chief Medical Officer | 540.0K | — | — | — | 315.9K | — | 855.9K | 0.00% | ↗ |
| 3 | 2025 | Jane Pritchett Henderson Chief Financial Officer | 540.0K | — | — | — | 315.9K | — | 855.9K | 0.00% | ↗ |
| 4 | 2024 | Michael Henderson, M.D. Chief Executive Officer | 661.5K | — | — | 12.00M | 545.7K | — | 13.21M | 90.86% | ↗ |
| 5 | 2024 | Carl Dambkowski, M.D. Chief Medical Officer | 525.0K | — | — | 4.20M | 354.4K | — | 5.08M | 82.69% | ↗ |
| 6 | 2024 | Jane Pritchett Henderson Chief Financial Officer | 525.0K | — | — | 4.20M | 354.4K | — | 5.08M | 82.69% | ↗ |
| 7 | 2023 | Michael Henderson, M.D. Chief Executive Officer Carl Dambkowski, M.D. Chief Medical Officer | 564.8K | 606.4K | — | 7.50M | — | — | 8.67M | 86.49% | ↗ |
| 8 | 2023 | Michael Henderson, M.D. Chief Executive Officer | 564.8K | 606.4K | — | 7.50M | — | — | 8.67M | 86.49% | ↗ |
| 9 | 2023 | Jane Pritchett Henderson Chief Financial Officer | 469.3K | 374.3K | 881.3K | 3.30M | — | — | 5.02M | 83.21% | ↗ |
| 10 | 2023 | Carl Dambkowski, M.D. Chief Medical Officer Jane Pritchett Henderson Chief Financial Officer | 477.1K | 393.8K | — | 3.30M | — | — | 4.17M | 79.12% | ↗ |
| 11 | 2023 | Carl Dambkowski, M.D. Chief Medical Officer | 477.1K | 393.8K | — | 3.30M | — | — | 4.17M | 79.12% | ↗ |
| 12 | 2022 | Michael Henderson, M.D. Chief Executive Officer Carl Dambkowski, M.D. Chief Medical Officer | 145.8K | 167.1K | 6.08M | — | — | 56.8K | 6.45M | 94.27% | ↗ |
| 13 | 2022 | Carl Dambkowski, M.D. Chief Medical Officer Jane Pritchett Henderson Chief Financial Officer | 176.3K | 212.9K | 1.19M | — | — | — | 1.58M | 75.43% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Michael Thomas Henderson | Chief Executive Officer & Director | 1M | — |
| Carl Linden Dambkowski | Chief Medical Officer | 855.9K | — |
| Jane Pritchett V. Henderson | Chief Financial Officer | 855.9K | female |
| Wendy Aspden-Curran | Senior Vice President of Clinical Operations | — | female |
| Matthew Batters | Chief Legal Officer & Corporate Secretary | — | male |
| Drew Badger | Senior Vice President and Head of Regulatory Affairs & Toxicology | — | — |
| Monica Forbes | Senior Vice President of Finance | — | female |
| Noel Kurdi | Vice President of Investor Relations | — | female |
| Rebecca Dabora | Chief Development Officer | — | — |
| Emily Cox | SVP & Head of People | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for APGE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
